Examples of what manufacturers must report to the MHRA under the medical device vigilance system when incidents involving their devices occur in the UK.
Similar Posts
MHRA and NICE invite early adopters to trial accelerated aligned pathway – six months ahead of schedule
Aligned pathway will streamline decisions on licensing and value for medicines, helping patients to benefit from them sooner.
AI Airlock, CERSIs and a new global AI network for health regulators
Med Tech Regs blog, June 2025: A focus on Software and AI.
Field Safety Notices: 02-06 February 2026
List of Field Safety Notices: 02-06 February 2026
MHRA publishes final Business Plan for 2023-2026 Corporate Plan
The new Business Plan sets out priorities for 2025–26: Protecting public safety and maintaining public trust; delivering efficient, predictable services through regulatory excellence; being an agile organisation that drives innovation; being a great place to work and providing excellent customer service.
Corporate report: MHRA Corporate Plan: 2023 to 2026 and Business Plan: 2025 to 2026
These reports outline the MHRA’s Corporate and Business Plans, detailing the agency’s strategic direction over the next three years.
MHRA approves sebetralstat (Ekterly) to treat hereditary angioedema (HAE) attacks in patients aged 12 and over
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 15 July 2025, approved sebetralstat (Ekterly) for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older.